{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:24:43Z","timestamp":1785461083596,"version":"3.56.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Burkholderia cepacia<\/jats:italic> complex is an aerobic, non\u2013spore-forming, catalase-positive, nonfermentative, Gram-negative bacterium common in environment. It is a serious pathogen especially for patients with cystic fibrosis (CF). But pathogenicity of <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> is not limited to patients with CF. Herein, we aimed to reveal clinical patterns and outcomes of <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> infections in pediatric patients in our hospital and also antimicrobial susceptibility of the isolated strain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective study was conducted in Ankara Hematology Oncology Children\u2019s Training and Research Hospital. Patients with isolates of <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> spp. between January 6, 2013, and January 12, 2018, were included in the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> spp. was isolated from 55 patients. 94.6% of these patients had underlying diseases and had prior hospitalization within a year. <jats:italic toggle=\"yes\">Burkholderia gladioli<\/jats:italic> grew in 15 patients\u2019 samples (27.3%); 38 patients grew <jats:italic toggle=\"yes\">B. cepacia<\/jats:italic> (69.1%). None of the patients that <jats:italic toggle=\"yes\">B. gladioli<\/jats:italic> was isolated was diagnosed as CF;. all had nosocomial infections. <jats:italic toggle=\"yes\">B. gladioli<\/jats:italic> seemed to be more susceptible to aminoglycosides, piperacillin-tazobactam, carbapenems and ciprofloxacin than <jats:italic toggle=\"yes\">B. cepacia<\/jats:italic> (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.00), whereas <jats:italic toggle=\"yes\">B. cepacia<\/jats:italic> seemed to be more susceptible to ceftazidime than <jats:italic toggle=\"yes\">B. gladioli<\/jats:italic> (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.032). In addition, <jats:italic toggle=\"yes\">B. cepacia<\/jats:italic> was more susceptible to trimethoprim-sulfamethoxazole and levofloxacin than <jats:italic toggle=\"yes\">B. gladioli<\/jats:italic>, but this difference was not statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.76).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The incidence of nosocomial infections caused by <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> spp. is rare especially in pediatric literature. In our study, nosocomial <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> infections occurred mostly in intensive care unit patients. The surveillance of <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> infections is still very important, and the clinicians should be aware of changing epidemiology and increasing resistance of the microorganism. Besides, there are no internationally agreed minimal inhibitory concentration breakpoints and disk-diffusion test thresholds for susceptibility testing for <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic>. Thus, the methods which were used for antibiotic susceptibility testing in our center might cause uncertainty about the results and internationally agreed minimal inhibitory concentration breakpoints and disk-diffusion test thresholds for susceptibility testing for <jats:italic toggle=\"yes\">Burkholderia<\/jats:italic> is still a gap to fill for the current literature.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002587","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T03:17:14Z","timestamp":1583119034000},"page":"374-378","source":"Crossref","is-referenced-by-count":9,"title":["Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children"],"prefix":"10.1097","volume":"39","author":[{"given":"Tugba","family":"Bedir Demirdag","sequence":"first","affiliation":[{"name":"Pediatric Infectious Disease Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslinur","family":"Ozkaya Parlakay","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Selcuk","family":"Aygar","sequence":"additional","affiliation":[{"name":"Microbiology Department, Ankara Hematology Oncology Children\u2019s Training and Research Hospital, Ankara, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belgin","family":"Gulhan","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Kanik Yuksek","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrmicro1085","article-title":"The multifarious, multireplicon Burkholderia cepacia complex.","volume":"3","author":"Mahenthiralingam","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1086\/322684","article-title":"Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans.","volume":"33","author":"Mahenthiralingam","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R3-20230912","first-page":"273","article-title":"Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance.","volume":"3","author":"Dizbay","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"R4-20230912","first-page":"299","article-title":"Burkholderia cepacia complex outbreaks among non-cystic fibrosis patients in the intensive care units: a review of adult and pediatric literature.","volume":"26","author":"Abdallah","year":"2018","journal-title":"Infez Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1017\/ice.2017.11","article-title":"An outbreak of Burkholderia cepacia Complex infections associated with contaminated liquid docusate.","volume":"38","author":"Marquez","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jhin.2017.09.012","article-title":"Outbreak of Burkholderia cepacia pseudobacteraemia caused by intrinsically contaminated commercial 0.5% chlorhexidine solution in neonatal intensive care units.","volume":"98","author":"Song","year":"2018","journal-title":"J Hosp Infect"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/JCM.02489-08","article-title":"Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli.","volume":"47","author":"Segonds","year":"2009","journal-title":"J Clin Microbiol"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1099-0496(199702)23:2<123::AID-PPUL9>3.0.CO;2-Q","article-title":"Lung infection with Burkholderia gladioli in a child with cystic fibrosis: acute clinical and spirometric deterioration.","volume":"23","author":"Barker","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1378\/chest.112.4.924","article-title":"Infections in patients with cystic fibrosis following lung transplantation.","volume":"112","author":"Kanj","year":"1997","journal-title":"Chest"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.inf.0000177285.44374.dc","article-title":"Burkholderia gladioli osteomyelitis in association with chronic granulomatous disease: case report and review.","volume":"24","author":"Boyanton","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1086\/515551","article-title":"Four additional cases of Burkholderia gladioli infection with microbiological correlates and review.","volume":"25","author":"Graves","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00003226-200208000-00014","article-title":"Burkholderia gladioli keratitis associated with consecutive recurrent endophthalmitis.","volume":"21","author":"Ritterband","year":"2002","journal-title":"Cornea"},{"key":"R13-20230912","first-page":"86","article-title":"Colonization and infection.","volume":"67","author":"Dani","year":"2014","journal-title":"Cent European J Urol"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4065\/81.4.529","article-title":"Vancomycin-resistant enterococci: colonization, infection, detection, and treatment.","volume":"81","author":"Zirakzadeh","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1183\/09059180.00006512","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis.","volume":"22","author":"Bhatt","year":"2013","journal-title":"Eur Respir Rev"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13104-017-2626-5","article-title":"Antimicrobial susceptibility pattern of clinical isolates of Burkholderia pseudomallei in Bangladesh.","volume":"10","author":"Dutta","year":"2017","journal-title":"BMC Res Notes"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"e00590","DOI":"10.1128\/AAC.00590-18","article-title":"In vitro susceptibility of Burkholderia cepacia Complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam.","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrobial Agents Chemother"},{"issue":"Suppl 1","key":"R22-20230912","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.mjafi.2016.03.003","article-title":"Report on the newly emerging nosocomial Burkholderia cepacia in a tertiary hospital.","volume":"72","author":"Srinivasan","year":"2016","journal-title":"Med J Armed Forces India"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15226\/2372-0948\/4\/2\/00151","article-title":"Nosocomial acquisition of Burkholderia gladioli bacteremia in two children without documented cystic fibrosis and immunedeficiency: case reports.","volume":"4","author":"Matijasic","year":"2016","journal-title":"SOJ Immunol"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3349\/ymj.2016.57.1.97","article-title":"Burkholderia Sepsis in children as a hospital acquired infection.","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.diagmicrobio.2011.01.008","article-title":"Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unit.","volume":"70","author":"Liao","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijantimicag.2008.09.010","article-title":"Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence.","volume":"33","author":"Avgeri","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2006.10.007","article-title":"Burkholderia Gladioli: five years experience in a cystic fibrosis and lung transplantation center.","volume":"6","author":"Kennedy","year":"2007","journal-title":"J Cyst Fibros"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jinf.2018.07.006","article-title":"Burkholderia cepacia complex infections: more complex than the bacterium name suggest.","volume":"77","author":"Sfeir","year":"2018","journal-title":"J Infect"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1128\/AAC.00766-17","article-title":"In vitro activity of Ceftolozane-Tazobactam and other antimicrobial agents against Burkholderia cepacia complex and Burkholderia gladioli.","volume":"61","author":"Mazer","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:56:21Z","timestamp":1694559381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002587","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}